Sodium oxybate is filed as Narcolepsy treatment. The sections below restate public label fields stored for this profile.
Sodium oxybate oral solution is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy. Pediatric use information is approved for Jazz Pharmaceuticals Inc.’s XYREM (sodium oxybate) Oral Solution. However, due to Jazz Pharmaceuticals Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Sodium oxybate is a CNS depressant. The mechanism of action of sodium oxybate oral solution in the treatment of narcolepsy is unknown. Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that the therapeutic effects of sodium oxybate on cataplexy and excessive daytime sleepiness are mediated through GABA B actions at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons.
WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION AND ABUSE AND MISUSE Central Nervous System Depression LUMRYZ (sodium oxybate) is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with LUMRYZ at recommended doses [see Warnings and Precautions (5.1) ] . Many patients who received sodium oxybate during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials (14) ] . Abuse and Misuse LUMRYZ (sodium oxybate) is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions (5.2) ] . Because of the risks of CNS depression and abuse and misuse, LUMRYZ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the LUMRYZ REMS [see Warnings and Precautions (5.3) ]. WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION AND ABUSE AND MISUSE See full prescribing information for complete boxed warning. Central Nervous System Depression • LUMRYZ is a CNS depressant, and respiratory depression can occur with LUMRYZ use ( 5.1 , 5.4 ) Abuse and Misuse • LUMRYZ is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB is associated with CNS adverse reactions, including seizure, respiratory depression, decreased consciousness, coma, and death ( 5.2 , 9.2 ) LUMRYZ is available only through a restricted program called the LUMRYZ REMS ( 5.3 )
BOXED WARNING: WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION AND ABUSE AND MISUSE Central Nervous System Depression LUMRYZ (sodium oxybate) is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with LUMRYZ at recommended doses [see Warnings and Precautions (5.1) ] . Many patients who received sodium oxybate during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials (14) ] . Abuse and Misuse LUMRYZ (sodium oxybate) is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions (5.2) ] . Because of the risks of CNS depression and abuse and misuse, LUMRYZ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the LUMRYZ REMS [see Warnings and Precautions (5.3) ]. WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION AND ABUSE AND MISUSE See full prescribing information for complete boxed warning. Central Nervous System Depression • LUMRYZ is a CNS depressant, and respiratory depression can occur with LUMRYZ use ( 5.1 , 5.4 ) Abuse and Misuse • LUMRYZ is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB is associated with CNS adverse reactions, including seizure, respiratory depression, decreased consciousness, coma, and death ( 5.2 , 9.2 ) LUMRYZ is available only through a restricted program called the LUMRYZ REMS ( 5.3 )
Sodium oxybate oral solution is contraindicated for use in: combination with sedative hypnotics [see Warnings and Precautions (5.1) ] . combination with alcohol [see Warnings and Precautions (5.1) ] . patients with succinic semialdehyde dehydrogenase deficiency [see Clinical Pharmacology (12.3) ] .
Adverse reactions for pediatric patients (≥ 5%); Leading to discontinuation was dizziness (4.7%); Ies with immediate-release sodium oxybate (≥2%); L trial the most common adverse reactions (≥5%); Were nausea (20%); Enuresis (19%); Vomiting (18%); Headache (17%)
The following clinically significant adverse reactions appear in other sections of the labeling: CNS depression [see Warnings and Precautions (5.1) ] Abuse and Misuse [see Warnings and Precautions (5.2) ] Respiratory Depression and Sleep-Disordered Breathing [see Warnings and Precautions (5.4) ] Depression and Suicidality [see Warnings and Precautions (5.5) ] Other Behavioral or Psychiatric Adverse Reactions [see Warnings and Precautions (5.6) ] Parasomnias [see Warnings and Precautions (5.7) ] Use in Patients Sensitive to High Sodium Intake [see Warnings and Precautions (5.8) ]
Dosage for Adult Patients Initiate dosage at 4.5 g per night orally, divided into two doses (2.1) . Titrate to effect in increments of 1.5 g per night at weekly intervals (0.75 g at bedtime and 0.75 g taken 2.5 to 4 hours later) (2.1) . Recommended dosage range: 6 g to 9 g per night orally (2.1) . Total Nightly Dose Take at Bedtime Take 2.5 to 4 Hours Later 4.5 g per night 2.25 g 2.25 g 6 g per night 3 g 3 g 7.5 g per night 3.75 g 3.75 g 9 g per night 4.5 g 4.5 g Important Administration Information Prepare both doses prior to bedtime; dilute each dose with approximately 1/4 cup of water in pharmacy-provided containers (2.3) . Allow 2 hours after eating before dosing (2.3) . Take each dose while in bed and lie down after dosing (2.3) . Patients with Hepatic Impairment Recommended starting dosage is one-half of the original dosage per night administered orally, divided into two doses (2.4) .
Concomitant use with divalproex sodium: An initial reduction in sodium oxybate oral solution dose of at least 20% is recommended (2.5 , 7.2) .
According to its FDA label, Sodium oxybate is approved for: Sodium oxybate oral solution is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy. Pediatric use information is approved for Jazz Pharmaceuticals Inc.’s XYREM (sodium oxybate) Oral Solution. However, due to Jazz Pharmaceuti… For medical advice, please talk to your prescriber or pharmacist.
Sodium oxybate belongs to the Narcolepsy treatment class of medications.
The FDA label lists Sodium oxybate as: CNS depression: Use caution when considering the concurrent use of sodium oxybate with other CNS depressants (5.1) . Caution patients against hazardous activities requiring complete mental alertness or motor coordination within the first 6 hours of dosing or after first initiating treatment until certain that sodium oxybate oral solution does not affect them adversely (5.1) . Depression and suicidality: Monitor patients for emergent or increased depression and suicidality (5.5) . Confusion/Anxiety: Monitor for impaired motor/cognitive function (5.6) . Parasomnias: Evaluate episodes of sleepwalking (5.7) . High sodium content in sodium oxybate oral solution: Monitor patients with heart failure, hypertension, or impaired renal function (5.8) .; oral route. Available strengths and packaging vary by manufacturer.
Yes. A generic version of Sodium oxybate is available in the U.S. Ask your pharmacist about substitution.
Yes. The FDA label for Sodium oxybate carries a Boxed Warning. Excerpt: "WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION AND ABUSE AND MISUSE Central Nervous System Depression LUMRYZ (sodium oxybate) is a CNS depressant. Clinically significant respiratory depression and obtundation may occur…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.
The FDA Enforcement Report does not show an active/ongoing recall for Sodium oxybate in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA record lists the approval date for Sodium oxybate as 2023-05-01.
The FDA label lists Avadel CNS Pharmaceuticals, LLC as a labeler/manufacturer of Sodium oxybate. Multiple firms may market generics of the same molecule.
The FDA label states: "Sodium oxybate oral solution is a clear, colorless to pale yellow oral solution. Each prescription includes one bottle of sodium oxybate oral solution, a press-in-bottle-adaptor, a 10 mL oral measuring device (plastic sy…" Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…